Immunological mechanisms in the aetiology of epilepsy: Implications for treatment

BioDrugs

Volumn 12, Issue 2, 1999, Pages 115-127

  Van Rijckevorsel, Kenou ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT;

ARTICLE; AUTOIMMUNE DISEASE; BRAIN INJURY; CORTICOSTEROID THERAPY; EPILEPSY; EPILEPTOGENESIS; GENETIC PREDISPOSITION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; PRIORITY JOURNAL; SEIZURE;

EID: 0032822684     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912020-00003     Document Type: Article

References (177)

1. Walker AE. Allergic phenomena as basic mechanisms in epilepsy, In: Jasper HH, Ward Jr AA, Pope A, editors. Basic Mechanisms of the Epilepsies. London: Churchill, 1969; 812
2. Lim R, de la Torre JC, Mullan S. Protein and enzyme alterations in experimental brain injury. Arch Neurol 1972; 27:314-21
3. Bowen FP. Immunologic reactions after cortical lesions in rabbits. Arch Neurol 1968; 19: 398-402
4. Proctor-Bowen F, Karpiak S, Gessinger J, et al. Epileptiform activity induced by intraventricular injection of antiserum to synaptosome membrane fraction. Proc Fed Am Soc Exp Biol 1971; 2: 30
5. Karpiak SE, Bowen FP, Rapport MM. Epileptiform activity induced by antisera to synaptic membrane. Brain Res 1973; 59: 303-10
6. Bowen FP, Kosarova J, Cassella D, et al. Focal epileptogenic activity induced by topical application of antisera to brain actomyosin-like protein. Brain Res 1976; 102: 363-7
7. Baltz ML, Ettlinger K, Parrish-Pepys MB, et al. Epileptic discharges produced in monkeys by injection of spleen cells from rabbits immunized with monkey brain. J Neurol Sci 1981; 49: 335-40
8. Karpiak SE, Graf L, Rapport MM, Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976; 194: 735-7
9. Karpiak SE, Mahadik SP, Graf L, et al. Immunological model of epilepsy: Seizures induced by antibodies to GMI ganglioside. Epilepsia 1981; 22: 189-96
10. Karpiak SE, Huang YL, Rapport MM. Immunological model of epilepsy. Epileptiform activity induced by fragments of antibody to GMI ganglioside. J Neuroimmunol 1982; 3: 15-21
11. Rappoport SI, editor. Blood-brain Barrier in Physiology and Medicine. New York: Raven Press, 1976; 316
12. Sokrab TE, Kalimo H, Johansson BB. Endogenous serum albumin content in brain after short-lasting epileptic seizures. Brain Res 1989; 489: 231-6
13. Ettlinger G, Lowrie MB. An immunological factor in epilepsy. Lancet 1976; 1: 1386
14. Vlajkovic S, Jankovic BD, Experimental epilepsy in vitro: Neuromodulating activity of anti-brain autoantibodies from rats exposed to electroconvulsive shock. Int J Neurosci 1991; 59: 205-11
15. Lowrie MB, Maccabe JJ, Ettlinger G. The effects of ablations on primary and secondary epileptic discharges in commissure-sectioned Rhesus monkeys. Electroencephalogr Clin Neurophysiol 1978; 44: 23-36
16. Moumdjian RA, Antel JP, Yong VW. Origin of contralateral reactive gliosis in surgically injured rat cerebral cortex. Brain Res 1991: 547: 223-8
17. Lowenstein DH. Recent advances related to basic mechanisms of epileptogenesis. Epilepsy Res 1996; 11 Suppl.: 45-60
18. Hrachovy RA, Frost D Jr J. Infantile spasms: A disorder of the developing nervous system. In: Kellaway P, Noebels JL, editors. Problems and Concepts in Developmental Neurophysiology. Baltimore (MD): Johns Hopkins University Press, 1989: 131-47
19. Glaze DG, Zion TE. Infantile spasms. Curr Probl Pediatr 1985; 15: 1-39
20. Fontana A, Fulpius BW, Cuénoud S. Antibodies against muscle and brain nicotinic acetyleholine receptors in IgA-deficient patients with epilepsy. Adv Cytopharmacol 1979; 3: 287-92
21. Plioplys AV, Greaves A, Yoshida W. Anti-CNS antibodies in childhood neurologic diseases. Neuropediatrics 1989; 20: 93-102
22. Xie XK, Tang LO. Observation on anti-brain antibody in serum of 110 epileptics. Clin Med J Engl 1990; 103: 71-5
23. Qu ZP, Yu LY, Lu CZ, et al. A preliminary observation on autocholinergic synapse dysfunction in patients with different types of epilepsy. Jpn J Psychiatry Neurol 1992; 46: 401-3
24. Bartolomei F, Boucraut J, Barrie M, et al. Cryptogenic partial epilepsies with anti-GMI antibodies: A new form of immune-mediated epilepsy? Epilepsia 1996; 37 (10): 922-6
25. Guillon B, de Ferron E, Feve JR, et al. Simple partial status epilepticus and antiglycolipid IgM antibodies: Possible epilepsy of autoimmune origin. Arch Neurol 1997; 54 (10): 1194-6
26. Giometto B, Nicolao P, Macucci M, et al. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 1998; 352 (9126):
27. Rogers SW, Hugues TE, Heineman SF, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648-51
28. Nevsimalova S, Tauberova A, Doutlik V, et al. A role of autoimmunity in the etiopathogenesis of Landau-Kleffner syndrome? Brain Dev 1992; 14 (5): 342-5
29. Twyman RE, Gahring LC, Spiess J, et al. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 1995; 14 (4): 755-62
30. Herranz MT, Rivier G, Khamashta MA, et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 568-571
31. Verrot D, San Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103 (1): 33-7
32. Mackworth-Young CG, Hughes GRV. Epilepsy: An early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1985; 48: 185
33. Aarli JA. Immunological aspects of epilepsy. Brain Dev 1993; 15 (1): 41-9
34. Iivanainen M, Hietala J, Malkamki M, et al. An association between epileptic seizures and increased serum bacterial antibody levels. Epilepsia 1983; 24: 84-587
35. Andersen P, Mosekilde L, Hjort T. Antibodies to Escherichia coli and serum immunoglobulin levels in epileptics on long-term anticonvulsant therapy. Clin Exp Immunol 1981; 45: 137-42
36. Andersen P, Alacam R, Andersen I, et al. Cytomegalovirus antibodies in epileptics receiving diphenylhydantoin. Acta Neurol Scand 1982; 66: 561-7
37. Bellman MH, Ross EM, Miller DL. Infantile spasms and pertussis immunisation. Lancet 1983; 11: 1031-4
38. Sanders VJ, Felisan SL, Waddell AE, et al. Presence of herpes simplex DNA in surgical tissue from human epileptic seizure foci detected by polymerase chain reaction: Preliminary study. Arch Neurol 1997; 54 (8): 954-60
39. Jay V, Hwang P, Hoffman HJ, et al. Intractable seizure disorder associated with chronic herpes infection. HSVI detection in tissue by the polymerase chain reaction. Childs Nerv Syst 1998; 14 (1-2): 15-20
40. Eeg-Olofsson O, Bergstrom T, Osterland CK, et al. Epilepsy etiology with emphasis on immune dysfunction and neurovirology. Brain Dev 1995; 17 Suppl.: 58-60
41. Beach TG, Woodhurst WB, MacDonald DB, et al. Reactive microglia in hippocampal sclerosis associated with human temporal lobe epilepsy. Neurosci Lett 1995; 191 (1-2): 27-30
42. Thatte U, Dahanukar S. Apoptosis: Clinical relevance and pharmacological manipulation. Drugs 1997; 54 (4): 511-32
43. Bird SJ. Clinical and electrophysiologie improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992; 42: 1422-3
44. + current in isolated rat myelinated nerve fibers. Ann Neurol 1995; 37: 436-42
45. Waxman SG. Sodium channel blockade by antibodies: A new mechanism of neuronal disease? Ann Neurol 1995; 37: 421-3
46. McEvoy KM, Stiff-man syndrome. Mayo Clin Proc 1991; 66: 300-4
47. Shmatko VG, Konev VP, Ereniev SI, et al. Morphological and immunological comparisons in epilepsy. Zh Nevropatol Psikhiatr 1991 91: 47-51
48. Gahring LC, White HS, Skradski SL, et al. Interleukin-1-alpha in the brain is induced by andiogenic seizure. Neurobiol Dis 1997; 3 (4): 263-9
49. de Bock F, Dornand J, Rondouin G. Release of TNF alpha in the rat hippocampus following epileptic seizures and excitotoxic neuronal damage. Neuroreport 1996; 7 (6): 1125-9
50. Sundar SK, Becker KJ, Cierpial MA, et al. Intracerebroventricular infusion of interleukin 1 rapidly decreases peripheral cellular immune responses. Proc Natl Acad Sci USA 1989; 86: 6398-402
51. Giulan D, Chen J, Ingeman JE, et al. The role of mononuclear phagocytes in wound healing after traumatic injury to adult mammalian brain. J Neurosci 1989; 9: 4416-29
52. Vlajkovic S, Jankovie BD. Experimental epilepsy: Electrically and chemically induced convulsions modulate experimental allergic encephalomyclitis and other immune inflammatory reactions in the rat. Int J Neurosci 1990; 54: 165-72
53. Rowland RR, Tokuda S, Weiss GK, et al. Evidence of immuno-suppression in the genetically epilepsy-prone rat. Life Sci 1991; 48: 1821-6
54. Razani-Boroujerdi S, Rowland RR, Ortiz KA, et al. Evidence of altered T-lymphocyte number and proliferative responses in genetically epilepsy-prone rats. J Neuroimmunol 1992; 37 (1-2): 93-7
55. Carr JA, Ortiz KA, Paxton LL, et al. Alterations in spleen norepinephrine and lymphocyte ['H]dihydroalprenolol binding site number in genetically epilepsy-prone rats. Brain Behav Immun 1993; 7 (2): 113-20
56. Basaran N, Hincal F, Kansu E, et al. Humoral and cellular immune parameters in untreated and phenytoin- or carbamazepine-treated epileptic patients. Int J Immunopharmacol 1994; 16 (12): 1071-7
57. Bostantjopoulos S, Hatzizisi O, Argyropoulos O, et al. Immunological parameters in patients with epilepsy. Funct Neurol 1994; 9 (1): 11-5
58. Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine. Clin Exp Immunol 1975; 20: 273-85
59. Massimo L, Pasino M, Rosanda-Vadale C, et al. Immunological side effects of anticonvulsants. Lancet 1976; 1: 860
60. Pelliccia A, Porro G, Tribalto M, et al. Immunological study of children with primary generalized epilepsy not submitted to anticonvulsant therapy. Preliminary contribution. Neuropsichiatr Infant 1980; 228-229: 781-6
61. Basaran N, Kansu E, Hincal F. Serum immunoglobulins, complement levels and lymphocyte subpopulations in phenytoin-treated epileptic patients. Immunopharmacol Immunotoxicol 1989; 11: 335-46
62. Basaran N, Hincal F, Kansu E, et al. Humoral and cellular parameters in untreated and phenytoin or carbamazepine treated epileptic patients. Int J Immunopharmacol 1994; 16 (12): 1071-7
63. Tyomin P, Stephany D, Vinogradova T, et al. The influence of anticonvulsants on the immunological status of children with epilepsy. Epilepsia 1995; 36 Suppl. 4: 125
64. Eeg-Olofsson O, Prchal JF, Andermann F. Abnormalities of T-lymphocyte subsets in epileptic patients. Acta Neurol Scand 1985; 72: 140-4
65. Margaretten NC, Warren RP. Reduced natural killer cell activity and OKT4/OKT8 ratio in epileptic patients. Immunol Invest 1986; 15: 159-67
66. Lenti C, Masserini C, Peruzzi C, et al. Effects of carbamazepine and valproate on immunological assessment in young epileptic patients. Ital J Neurol Sci 1991; 12 (1): 87-91
67. Pacifici R, Zuccaro P, Iannetti P, et al. Immunologic aspects of vigabatrin in epileptic children. Epilepsia 1995; 36 (4): 423-6
68. Pruneri C, Zamperetti M, Stangherlin ML, et al. Natural killer cell (NK) activity in epileptic patients. Boll Lega Ital Epilessia 1985; 51-52: 241-2
69. Pacifici R, Paris L, Di Carlo S, et al. Immunologic aspects of carbamazepine treatment in epileptic patients. Epilepsia 1991; 32 (1): 122-7
70. Garcia Rodriguez MC, de la Concha EG, Fontan G, et al. Transient hypogammaglobulinemia in the adult. Functional assessment of T and B lymphocytes. J Clin Lab Immunol 1983; 11: 55-8
71. Guerra IC, Fawcett WA. Permanent intrinsic B-cell immunodeficiency caused by phenytoin hypersensitivity. J Allergy Clin Immunol 1986; 77: 603-8
72. Carlander B, Baldy-Moulinier M, Clot J, et al. Reduced peripheral blood B-lymphocytes in untreated epileptics. XVIIth Epilepsy International Congress 1987; 19
73. Xic X. An immunologic study of patients with epilepsy. Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1990; 23: 182-4, 191-2
74. Ambrus M, Hernadi E, Bajtai G. Prevalence of HLA-AI and HLA-B8 antigens in selective IgA deficiency. Clin Immunol Immunopathol 1977; 7: 311-4
75. Roberton DM, Colgan T, Ferrante A, et al. IgG subclass concentrations in absolute, partial and transient IgA deficiency in childhood. Pediatr Infect Dis J 1990; 9: S41-S5
76. Matsuoka H, Okada J, Takahashi T, et al. Immunological study of IgA deficiency during anticonvulsant therapy in epileptic patients. Clin Exp Immunol 1983; 53: 423-8
77. Slavin BN, Fenton GM, Laundy M, et al. Serum immunoglobulins in epilepsy. J Neurol Sci 1974; 23: 353-7
78. Seager J, Wilson J, Jamison DL, et al. IgA deficiency, epilepsy, and phenytoin treatment. Lancet 1975; 11: 632-5
79. Bassanini M, Baez A, Sotelo J. Immunoglobulins in epilepsy. J Neurol Sci 1982; 56: 275-81
80. Badawy AH, Shalaby SA, Abdel-Aal SF. Hydantoin immuno-suppression clinical study. J Egypt Soc Parasitol 1991; 21 (1): 257-62
81. Fontana A, Fulpius BW. Epilepsy, IgA deficiency, histocompatibility antigens and anti-acetylcholine receptor antibodies. In: Wada JA, Penry JK, editors. Advances in Epileptology. Xth Epilepsy International Symposium. New York: Raven Press, 1980: 544-5
82. Gilhus NE, Aarli J, Thorsby E. HLA antigens in epileptic patients with drug-induced immunodeficiency. Int J Immunopharmacol 1982; 4: 517-20
83. Ariizumi M, Kuromori N, Utsumi Y, et al. CSF IgG in febrile convulsion and childhood epilepsy. Acta Neurol Scand 1980; Suppl. 79: 79-80
84. Fontana A, Grob PJ, Sauter R. Immunoglobulin abnormalities in relatives of IgA deficient epileptics. J Neurol 1978; 217: 207-12
85. Gilhus NE, Aarli JA. Immunoglobulin concentrations in patients with a history of febrile convulsions prior to the development of epilepsy. Neuropediatrics 1981; 12: 314-8
86. Tartara A, Verri AP, Nespoli L, et al. Immunological findings in epileptic and febrile convulsion patients before and under treatment. Eur Neurol 1981; 20: 306-11
87. Haldorsen T, Aarli JA. Immunoglobulin concentrations in first-degree relatives of epileptic patients with drug-induced IgA deficiency. Acta Neurol Scand 1977; 56: 608-12
88. Ariizumi M, Matsuda H, Osawa A, et al. Serum IgA levels in childhood epilepsy. Excerpta Medica 1977; 63: 427
89. Fontana A, Grob PJ, Sauter R. Immunoglobulin abnormalities in epileptics. In: Meinardi H, Rowan AJ, editors. Advances in Epileptology. Amsterdam: Swets & Zeitlinger, 1977: 354-8
90. Fontana A, Joller H, Skvaril F, et al. Immunological abnormalities and HL antigen frequencies in IgA deficient patients with epilepsy. J Neurol Neurosurg Psych 1978; 41: 593-7
91. Shakir RA, Behan PO, Dick H, et al. Metabolism of immunoglobulin A, lymphocyte function, and histocompatibility antigens in patients on anticonvulsivants. J Neurol Neurosurg Psych 1978; 41: 307-11
92. Kanoh T, Uchino H. Immunodeficiency and epilepsy. Lancet 1976; 1: 860-1
93. Dosch HM, Jason J, Gelfand EW. Transient antibody deficiency and abnormal T suppressor cells induced by phenytoin. N Engl J Med 1982; 306: 406-9
94. Gilhus NE, Aarli JA. The reversibility of phenytoin-induced IgA deficiency. J Neurol 1981; 226: 53-61
95. Macoka Y, Hara T, Dejima S, et al. IgA and IgG2 deficiency associated with zonisamide therapy: A case report. Epilepsia 1997; 38 (5): 611-5
96. Talesnik E, Rivero SJ, Gonzalez B. Serum IgA deficiency induced by prolonged phenytoin treatment. Rev Invest Clin 1989; 41: 331-5
97. Kondo N, Takao A, Tomatsu S, et al. Suppression of IgA production by lymphocytes induced by diphenylhydantoin. J Invest Allergol Clin Immunol 1994; 4 (5): 255-7
98. Aarli JA. Drug-induccd IgA deficiency in epileptic patients. Arch Neurol 1976; 33: 296-9
99. Ostergaard PA. Clinical and immunological features of transient IgA deficiency in children. Clin Exp Immunol 1980; 40: 561-4
100. Plebani A, Ugazio AG, Monafo V, et al. Clinical heterogeneity and reversibility of selective immunoglobulin A deficiency in 80 children. Lancet 1986; 1: 829-31
101. Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine. Clin Exp Immunol 1975; 20: 273-85
102. Aarli JA, Fontana A. Immunological aspects of epilepsy. Epilepsia 1980; 21: 451-7
103. Gilhus NE, Aarli JA. Respiratory disease and nasal immunoglobulin concentrations in phenytoin-treated epileptic patients. Acta Neurol Scand 1981; 63 (1): 34-43
104. Gilhus NE, Strandjord RE, Aarli JA, Respiratory disease in patients with epilepsy on single-drug therapy with carbamazepine or phenobarbital. Eur Neurol 1982; 21: 284-88
105. Lenti C, Masserini C, Peruzzi C, et al. Effects of carbamazepine and valproate on immunological assessment in young epileptic patients. Ital J Neurol Sci 1991; 12: 87-91
106. Paris L, Giardina M, Pacifici R, et al. Epileptic patients refractory to drug therapy. Ital J Neurol Sci 1991; 12 (5): 447-51
107. Duse M, Tiberti S, Plebani A, et al. IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy 1986; 20: 128-34
108. Dalla Bernadina B, Andrighetto G, Fontana E, et al. Intravenous gammaglobulin in early childhood intractable epilepsies. XVIIth Epilepsy International Symposium, 1987; Jerusalem: 29
109. Galeone D, Torelli D, Panaro A, et al. High-dose intravenous immunoglobulins therapy in children with intractable epilepsy associated with IgG2 deficiency. XVIIth Epilepsy International Symposium, 1987; Jerusalem, 44
110. Gilhus NE, Lea T. Carbamazepine: Effect on IgG subclasses in epileptic patients. Epilepsia 1988; 29: 317-20
111. Gilhus NE, Lea T. IgG subclasses in epileptic patients treated with phenytoin. J Neurol 1989; 236: 149-52
112. Wu HM, Liu CS, Sun MH, et al. Effects of lamotrigine on immunologic aspects in 20 patients with refractory epilepsy. Epilepsia 1997; 38 Suppl. 3: 79
113. Greenberg DA, Durner M, Shinnar S, et al. Association of HLA class II alleles in patients with juvenile myoclonic epilepsy compared with patients with other forms of adolescent-onset generalized epilepsy. Neurology 1996; 47 (3): 750-5
114. Fichsel H, Kessler M. HLA in primary generalized and partial epilepsy. In: Akimoto H, Kazamatsuri H, Seino M, et al. editors. Advances in Epileptology. XIIIth Epilepsy International Symposium. New York: Raven Press, 1982; 91-2
115. Eeg-Olofsson O, Soefwenberg J, Wigertz A. HLA and epilepsy: An investigation of different types of epilepsy in children and their families. Epilepsia 1982; 23: 27-34
116. Minev M, Martinova F, Belopitova L. On the association of the HLA system with epilepsy in children. Epilepsia 1987; 28: 74-6
117. Van Engelen BG, de Waal LP, Weemaes CM, et al. Serologic HLA typing in cryptogenic Lennox-Gastaut syndrome. Epilepsy Res 1994; 17 (1): 43-7
118. van Rijckevorsel K, Delire M. HLA in severe epilepsy and response to IVIG treatment. Epilepsia 1994; 35 Suppl. 7: 11
119. Weissbecker KA, Durner M, Janz D, et al. Confirmation of linkage between juvenile myoclonic epilepsy locus and the HLA region of chromosome 6. Am J Med Genet 1991; 38 (1): 32-6
120. Delgado-Escuota AV, Serratosa JM, Liu A, et al. Progress in mapping human epilepsy genes. Epilepsia 1994; 35 Suppl. 1: 29-40
121. Klein R, Livingston S. The effect of adrenocorticotropic hormone in epilepsy. J Pediatr 1950; 37: 733-42
122. Sorel L, Dusaucy-Bauloye A. A propos de 21 cas d'hypsarythmia de Gibbs: Son traitement spectaculaire par l' ACTH. Acta Neurol Psychiatr Belg 1958; 58: 130-41
123. Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): Effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994; 44 (6): 1030-6
124. Lerman P, Lerman-Sagie T, Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol 1991; 33 (3): 257-60
125. Hrachovy RA, Frost JD, Kellaway P, et al. A controlled study of ACTH therapy in infantile spasms. Epilepsia 1980; 21: 631-6
126. Glaze DG, Hrachovy RA, Frost JD, et al. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988; 112 (3): 389-96
127. Rijkonen RS, Soderstrom S, Vanhala R, et al. West syndrome: Cerebrospinal fluid nerve growth factor and effect of ACTH. Pediatr Neurol 1997: 17 (3): 224-9
128. Joels M, de Kloct ER. Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems. Prog Neurobiol 1994; 43 (1): 1-36
129. Martin MG, WU SV, Walsh JH. Hormonal control of intestinal Fe receptor gene expression and immunoglobulin transport in suckling rats. J Clin Invest 1993; 91 (6): 2844-9
130. Calixto Gonzalez E, Brailowsky S. Neurosteroids. Neuromodulators of cerebral excitability. Gac Med Mex 1998; 134 (1): 69-84
131. Baram TZ. Pathophysiology of massive infantile spasms: Perspective on the putative role of the brain adrenal axis. Ann Neurol 1993; 33: 231-6
132. Hollrigel GS, Chen K, Baram TZ, et al. The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of the rat. Neuroscience 1998; 84 (1): 71-9
133. Pieretti S, DI Giannuario A, Loizzo A, et al. Dexamethasone prevents epileptiform activity induced by morphine in in vivo and in vitro experiments. J Pharmacol Exp Ther 1992; 263 (2): 830-9
134. Crosley CJ, Richman RA, Thorpy MJ. Evidence for cortisol-independent anticonvulsant activity of adrenocorticotropic hormone in infantile spasms. Ann Neurol 1980; 8 (2): 220
135. Farwell J, Milstein J, Opheim K, et al. Adrenocorticotropic hormone controls infantile spasms independently of cortisol stimulation. Epilepsia 1984; 25 (5): 605-8
136. Heiskala H. CSF ACTH and beta-endorphin in infants with West syndrome and ACTH therapy. Brain Dev 1997; 19 (5): 339-42
137. Baram TZ, Mitchell WG, Hanson RA, et al. Cerebrospinal fluid corticotropin and cortisol are reduced in infantile spasms. Pediatr Neurol 1995; 13 (2): 108-10
138. Andrews PI, Dichter MA, Berkovic SF, et al. Plamapheresis in Rasmussen's encephalitis. Neurology 1996; 46 (1): 242-6
139. Campbell M, Krauss GL, Niedermeyer E. Treatment of Rasmussen's syndrome with seizures and aphasia with I.V. cyclophosphamide therapy. Epilepsia 1994; 35 Suppl 8: 50
140. Dabbagh O, Gascon G, Crowell J, et al. Intraventricular interferon-alpha stops seizures in Rasmussen's encephalitis: A case report. Epilepsia 1997; 38 (9): 1045-9
141. Andersson VG, Björk L, Skansen-Saphir U, et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-6
142. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-16
143. Péchadre JC, Sauvezic B, Osier C, et al. Traitement des encéphalopathies épileptiques de l'enfant par les gamma-globulines. Rev EEG Neurophysiol 1977; 7: 443-7
144. Ariizumi M, Shiira H, Hibio S, et al. High-dose gammaglobulin for intractable childhood epilepsy. Lancet 1983; 11: 162-3
145. Sandstedt P, Kostulas V, Larsson LE. Intravenous gammaglobulin for post-encephalitic epilepsy. Lancet 1984; 11: 1154-5
146. Plebani A, Duse M, Tiberti S, et al. Intravenous gamma-globulin therapy and serum IgG subclass levels in intractable childhood epilepsy. Monogr Allergy 1988; 23: 204-15
147. van Rijckevorsel K, Delire M, Sindic CJM, et al. Intravenous immunoglobulins in intractable epilepsy. Adv Epileptol 1989; 17: 336-9
148. van Rijckevorsel K, Delire M, Schmitz-Moorman W, et al. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994; 24: 162-6
149. Walsh PJ. Treatment of Rasmussen's syndrome with intravenous gammaglobulin. In: Andermann F, editor. Chronic Encephalitis and Epilepsy: Rasmussen's Syndrome. Boston: Butterworth-Heinemann 1991; 201-4
150. Wise MS, Rutledge SL, Kuzniecky RI. Rasmussen syndrome and long-term response to gamma globulin. Pediatr Neurol 1996; 14 (2): 149-52
151. Carabello R, Tenembaum S, Cers'osimo R, et al. Rasmussen syndrome. Rev Neurol 1998; 26 (154): 978-83
152. Fayad MN, Choueiri R, Mikati M. Landau-Kleftner syndrome: Consistent response to repeated intravenous γ-globulin doses: A case report. Epilepsia 1997; 38 (4): 489-94
153. Lagae LG, Silberstein J, Gillis PL, et al. Successful use of intravenous immunoglobulins in Landau-Kleffner syndrome. Pediatr Neurol 1998; 18 (2): 165-8
154. Ariizumi M, Hibio S, Ogawa K, et al. Comparative study on non-treated and pepsin-treated immunoglobulin therapy for idiopathic Lennox syndrome. Brain Dev 1984; 6: 422-3
155. Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180-6
156. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340 (3): 227
157. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683-9
158. Van Engelen BG, Renier WO, Weemacs CM, et al. Cerebrospinal fluid examinations in cryptogenic West and Lennox-Gastaut syndrome before and after intravenous immunoglobulin administration. Epilepsy Res 1994; 18 (2): 139-47
159. Hirayama H, Kurimoto T, Wada S, et al. Antiepileptic effects of globulin-N, an intact human immunoglobulin and its tissue-distribution in kindled cats. Int J Clin Pharmacol Ther Toxicol 1986; 24 (3): 109-22
160. Aarli JA, Aparicio S, Lumsden E, et al. Binding of normal human IgG to myelin sheaths, glia and neurons. Immunology 1976; 28: 1171-85
161. Rodriguez M, Lennon VA. Immunoglobulin promote remyclination in the central nervous system. Ann Neurol 1990; 27: 110-7
162. Hibio S, Michihiro N, Ogawa K, et al. Clinical effects and serum immunoglobulin changes following non-treated immunoglobulin administration in West syndrome. Brain Dev 1985; 7 (2): 183
163. van Rijckevorsel K, Delire M, Ruequoy-Ponsar M. Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins. Eur Arch Psychiatr Neurol Sci 1986; 236: 119-22
164. Baldy-Moulinier M, Parayre-Chanez MS, Echenne B, et al. Use of intravenous immunoglobulins in treatment of West and Lennox Gastaut syndromes. XVIIth Epilepsy International Symposium, 1987; Jerusalem, 19
165. Schwartz SA, Gordon KE, Johnston MV, et al. Use of intravenous immune globulin in the treatment of seizure disorders. J Allergy Clin Immunol 1989; 84: 603-7
166. Fois A, Vascotto M. Use of intravenous immunoglobulins in drug-resistant epilepsy. Childs Nerv Syst 1990; 6: 400-5
167. Sterio M, Gebauer E, Vucicevic G, et al. Intravenous immunoglobulin in the treatment of malignant epilepsy in children. Wien Klin Wochenschr 1990; 102: 230-3
168. Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: A single blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990; 21: 87-90
169. Etzioni A, Jaffe M, Pollack S, et al. High dose intravenous gamma-globulin in intractable epilepsy of childhood. Eur J Pediatr 1991; 150: 681-3
170. Echenne B, Dulac O, Parayre-Chanez MJ, et al. Treatment of infantile spasms with intravenous gamma-globulins. Brain Dev 1991; 13: 313-9
171. Gross-Tsur V, Shalev RS, Kazir E, et al. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 1993; 88 (3): 204-9
172. Voit T. High-dose immunoglobulin therapy of epilepsy in children. Infusionsther 1993; 20 Suppl. 1: 146-9
173. Van Engelen BG, Renier WO, Weemacs CM, et al. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on therapy. Eur J Pediatr 1994; 153 (10): 762-9
174. Munn R, Doucette J, Connolly M, et al. Controlled study of intravenous immunoglobulin in children with intractable generalized epilepsy. Epilepsia 1995; 36 Suppl. 4: 106
175. Nieto M, Candau R, Rufo M, et al. Intravenous immunoglobulin in severe myoclonic epilepsy of infancy. Epilepsia 1996; 37 Suppl. 4: 102
176. Turquay S, Baskin E, Dener S, et al. Immune globulin treatment in intractable epilepsy of childhood. Turk J Pediatr 1996; 38 (3): 301-5
177. Tyomin P, Krapivkine A, Perminov V, et al. High dose intravenous immune globulin (IVIG) in the treatment of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 1997; 38 (S3): 39